Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results
Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data
Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results
Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile
AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients
AstraZeneca; AZD0120; GC012F; dual-targeting CAR-T; BCMAxCD19; multiple myeloma; DURGA-1; China; Western patients; response rate; clinical trial; CAR-T
Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data
Biogen; Stoke Therapeutics; zorevunersen; Dravet syndrome; epilepsy; antisense oligonucleotide; seizure reduction; blockbuster drug; EMPEROR Phase III trial; American Epilepsy Society 2025; Jefferies analysts; natural history controls; SCN1A
German Court Blocks Merck’s Subcutaneous Keytruda Over Patent Dispute with Halozyme
Merck; Keytruda SC; Halozyme; Germany; patent infringement; preliminary injunction; Munich Regional Court; subcutaneous formulation; cancer drug; MDASE patents
Recent news on Biopharma Sentiment Index (BPSI)
Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook
Recent news on ACIP’s hepatitis B birth‑dose recommendation
ACIP; hepatitis B; birth dose; infant vaccination; shared clinical decision-making; CDC immunization schedule; pregnancy screening; hepatitis B policy change
Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219
Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials
Building the Next Generation of Biologics: Inside the Future of Protein Engineering
next-generation biologics; protein engineering; bispecific antibodies; antibody-drug conjugates (ADCs); protein degraders; PROTACs; molecular glues; mini-proteins; AI in protein design; manufacturability; structural biology; cryo-EM; high-throughput protein production; generative biology
UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance
UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships